Navigation Links
Gerresheimer Achieves Sales Target for 2009
Date:2/9/2010

    DUSSELDORF, Germany, February 9 /PRNewswire-FirstCall/ --
    - Profit Margin Better Than Expected

    - Sales on like-for-like basis almost at prior year level (-1.5 percent)
    - Adjusted EBITDA margin of 19.2 percent (on like-for-like basis) better
      than expected
    - CEO Dr. Axel Herberg: "We have demonstrated our stability and
      profitability in a difficult environment."
    - Outlook for 2010: sales increase of 2 to 4 percent and Adjusted EBITDA
      margin of mid 19 percent

In the economically challenging environment of the past year, Gerresheimer AG has achieved its sales target and turned in a better operating margin than expected.

Group sales in the past financial year (to the end of November) reached EUR1 billion. The pharma business, which now accounts for around three quarters of Group sales, again ensured a slight growth in sales in 2009. In contrast, the cyclical fields of cosmetics and Life Science Research suffered a fall in sales. On a like-for-like basis, i.e. excluding the Technical Plastics Systems business which was sold as per July 1, 2009, sales were 1.5 percent down on the prior year (forecast -1.5 to -2.5 percent).

The good operating margin (Adjusted EBITDA Margin), which at 19.2 percent exceeded the forecast of around 18.5 percent on a like-for-like basis, was achieved through early realignment of production capacity and cost reductions. Overall, however, there was a year-on-year fall in the operating result (Adjusted EBITDA) at EUR185.9m (2008: EUR206.4m). In contrast, net income rose substantially from EUR4.5m to EUR7.0m because of reduced one-off expenses. As a result, earnings per share increased from EUR0.02 to EUR0.18.

Gerresheimer further improved its finance structure over the past financial year. The equity ratio is at the comfortable level of 35.8 percent (prior year 31.6 percent). Net financial debt was reduced by EUR48.3m to EUR373.3m. Investment at the same time reached the high level of EUR86.4m.

Because of the decline in operating results and in order to strengthen the financial base for future growth opportunities, the Management Board and Supervisory Board recommends the Annual General Meeting that no dividend for the financial year 2009 is paid. Basically, however, Gerresheimer does intend to distribute attractive dividends again in the future, depending on the success of business.

"Overall we have demonstrated our stability and profitability in a difficult environment. We have successfully managed to create the conditions for future growth through targeted investments in our product portfolio and new plants throughout the world," says CEO Dr. Axel Herberg.

Broader product portfolio and internationalization

Gerresheimer constantly widens its product portfolio and expands into all the important strategic regions. In the financial year 2009 for example a third production line was completed for prefillable syringes, production capacity was built up for two insulin pen systems and investments were made in new products in the field of diabetes diagnostics. Within the parameters of the continued international orientation, three new locations were established in three continents. In China a state-of-the-art plant was constructed for pharmaceutical tubular glass. A new research and development center for medical plastic systems was opened in the USA and a new production center for pharmaceutical plastic packaging in Spain. In Brazil, a new production facility for insulin pen systems is planned for early 2010.

Outlook for 2010

The negative effects of the global financial and economic crisis should gradually abate and a revival in demand is now likely.

While Gerresheimer again expects growth for the pharma market, the outlook for cosmetics and Life Science Research is more difficult. Against this background the Management Board expects for the current financial year a sales increase of 2 to 4 percent (in relation to adjusted sales excluding Technical Plastic Systems of EUR970.8m) and an improved operating margin (Adjusted EBITDA Margin) of around 19.5 percent. Investment will total around EUR75m to 80m.

About Gerresheimer

Gerresheimer employs around 9,400 people in 40 locations in Europe, Americas and Asia. In the financial year 2009, worldwide sales totaled EUR1 billion. The product portfolio ranges from pharmaceutical vials made of glass and plastic through to complex drug-delivery systems for the pharma & healthcare industry. These include sterile syringes, inhalers and other system-based approaches for safe dosage and application of medications. The Group enjoys a leading position in markets which are characterized by high technical and regulatory barriers.

    Group Key Figures (IFRS; Financial Year end November 30)

    in EUR million                     FY 2009  FY 2008        %
    Sales                              1,000.2  1,060.1     -5.7
      Group sales excluding
      Technical Plastics[1]              970.8    985.9     -1.5

    Adjusted EBITDA[2]                   185.9    206.4     -9.9
      in % of sales                       18.6     19.5

    Adjusted EBITDA[2] excluding         186.2     n/a[3]
      Technical Plastics
      in % of sales                       19.2     n/a[3]

    Profit from operations (EBIT)         60.4     61.0     -1.0
    Net income                             7.0      4.5    +55.6
    Adjusted net income[4]                45.2     61.4    -26.4
    Earnings per share in EUR             0.18     0.02    >+100
    Adjusted earnings per share[5] in
      in EUR                              1.34     1.83    -26.8
    Equity ratio in %                     35.8     31.6
    Net financial debt                   373.3    421.6    -11.5
    Capital expenditure                   86.4    107.8    -19.9


    1 The Technical Plastic Systems segment was sold with effect from July 1,
      2009

    2 Adjusted EBITDA: Earnings before income taxes, financial result,
      amortization of fair value adjustments, extraordinary depreciation,
      depreciation and amortization, restructuring expenses and one-off
      income and expenses

    3 The adjusted EBITDA of the Technical Plastic Systems segment of the
      prior year is not available due to the fact that the divestment was
      carried out in the course of the financial year 2008 and is therefore
      included in the Plastic Systems segment

    4 Adjusted net income: Consolidated profit before non-cash amortization
      of fair value adjustments, special effects from restructuring expenses,
      extraordinary depreciation, the balance of one-off income and expenses
      (including significant non-cash expenses) and the related tax effects

    5 Adjusted net income after minorities divided by 31.4m shares


    Contact Press
    Burkhard Lingenberg
    Director Corporate Communication & Marketing Director
    Phone +49-211-6181-250
    Fax +49-211-6181-241
    e-mail b.lingenberg@gerresheimer.com

    Contact Investor Relations
    Anke Linnartz
    Corporate Investor Relations
    Phone +49-211-6181-314
    Fax +49-211-6181-121
    e-mail a.linnartz@gerresheimer.com


SOURCE Gerresheimer AG


'/>"/>
SOURCE Gerresheimer AG
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Gerresheimer has Passed the Turning Point
2. Mirixa Australia Achieves Six Month Milestones
3. Stemedica Achieves Major Milestone - Company Receives License to Manufacture Clinical Grade Stem Cells
4. NOVAVAX Achieves Pandemic H1N1 Influenza Production Milestone
5. EUCODIS Bioscience Achieves Development Milestone in Second Collaboration With Lohmann Animal Health
6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
7. Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients
8. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
9. Glycotex Investigational Compound GLYC-101 Achieves Accelerated Wound Closure Based on Interim Analysis
10. Semafore Achieves a Preclinical Milestone with SF2626, a PI3K-MEK Dual Pathway Kinase Inhibitor
11. Prescient Medical Achieves Milestones in Clinical Studies of vProtect(TM) Luminal Shield
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , Feb. 11, 2016 ... Companion Diagnostics in Personalized Medicine and Cancer Therapy. ... - High-Growth Diagnostic Testing Markets. - Key Diagnostic ... - Molecular Diagnostics in Genetic Testing. - ... Diagnostics Markets. - Over-the-Counter Diagnostic Products World Markets. ...
(Date:2/11/2016)... FRANCISCO , Feb. 11, 2016  Kindred Biosciences, ... on saving and improving the lives of pets, today ... Section of the New Animal Drug Application (NADA) for ... pivotal field study (KB0120) of Zimeta for the control ... the Company. --> --> ...
(Date:2/11/2016)... Calif. , Feb. 11, 2016  NOIT™ Research ... a special "Gift of Change" campaign to assist needy ... For every such unit sold between February 10, 2016 ... unit to a needy family. The NOIT is an ... non/limited-verbal autistic individuals develop language skills. ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... 12, 2016 , ... According to an article published February 4th ... significant portion of hernia repairs throughout the United States. Commenting on this article, Beverly ... that this trend has not only been expected, but it seems to be a ...
(Date:2/12/2016)... Boca Raton, FL (PRWEB) , ... February 12, ... ... nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving ... patient services – hosted over 250 members of South Florida’s philanthropic community at ...
(Date:2/12/2016)... ... February 12, 2016 , ... As a former television executive, owner Tal Rabinowitz ... no time to decompress, Rabinowitz found herself drawn to a casual meditation class while ... on her life, implementing a 20-minute-per-day meditation practice with her team. After her tenure ...
(Date:2/12/2016)... Miami, FL (PRWEB) , ... February 12, 2016 ... ... Workspace as a Service (WaaS), today announced the integration of Clarity Intelligence Platform ... itopia’s channel partners to offer real-time business intelligence (BI) to their small and ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... The Jones ... other communities across eastern Texas, is launching a cooperative charity drive with the Tarrant ... , Serving more than 50,000 individuals and families in need, the Tarrant County Food ...
Breaking Medicine News(10 mins):